ARTV
Artiva Biotherapeutics, Inc
Artiva Biotherapeutics, Inc historical holders
total: 1
Viking Global Investors Artiva Biotherapeutics, Inc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
Ole Andreas Halvorsen has been an institutional investor in Artiva Biotherapeutics, Inc (ARTV) since 2026 Q2. According to 2026 Q2 report, Ole Andreas Halvorsen holds 2,604,166 shares with a market value of roughly $25.26M representing 0.07% of their equity portfolio. The fund/company first acquired ARTV in 2026 Q2, initially purchasing about 2.60M shares.
Does Ole Andreas Halvorsen still hold ARTV?
Yes, Ole Andreas Halvorsen continues to hold Artiva Biotherapeutics, Inc (ARTV). According to their 2026 Q2 report, they maintain a position of 2,604,166 shares valued at approximately $25.26M, representing 0.07% of their equity portfolio.
When did Ole Andreas Halvorsen first invest in ARTV?
Ole Andreas Halvorsen first invested in Artiva Biotherapeutics, Inc (ARTV) in 2026 Q2 at the reported quarter-end price of $9.70 per share, acquiring 2,604,166 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for ARTV?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Artiva Biotherapeutics, Inc (ARTV) is approximately $9.70 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $9.70
ARTV transactions history by Viking Global Investors
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.07%
|
2,604,166
|
$9.70
|
$25,260,410
|
new
|
+0.07%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.